Increasing prevalence of HPV infection and cervical cancer globally is expected to drive the growth of the HPV testing and Pap test market. Furthermore, rising awareness about the importance of early detection and prevention of cervical cancer among women is also contributing to the market growth. In addition, technological advancements in HPV testing and development of more accurate and reliable testing methods are providing lucrative growth opportunities for market players.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Test Type, Application, Product, Technology, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Abbott, QIAGEN, BD, Quest Diagnostics Incorporated, Hologic,, F. Hoffmann-La Roche, Femasys, Arbor Vita, NURX, Seegene, Thermo Fisher Scientific, BioMérieux |
The high cost associated with HPV testing and Pap tests is a major restraint for market growth. Limited access to healthcare facilities, especially in developing countries, is also hindering the market growth. Moreover, social stigma and lack of awareness about cervical cancer screening among certain population groups are further restraining the growth of the HPV testing and Pap test market.